High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

• Status: Completed
• Trial end date: 2004-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of two dose schedules of activated recombinant human factor VII in treatment of joint bleeds in haemophilia patients with inhibitors.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Diagnosed of congenital haemophilia A or B with inhibitors to factor VIII or IX, respectively

• A history of 3 or more joint bleeds during the last 12 months

Exclusion Criteria:

• Joint bleeding within 7 days prior to trial start

• Treatment for bleeds within the last 5 days prior to trial start

• Clinically relevant coagulation disorders other than congenital haemophilia A or B